A study to evaluate and compare the anti-Xa activity and serum levels in patients receiving Apixaban 5 mg twice daily or rivaroxaban 20 mg once daily

Trial Profile

A study to evaluate and compare the anti-Xa activity and serum levels in patients receiving Apixaban 5 mg twice daily or rivaroxaban 20 mg once daily

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2017 New trial record
    • 01 Oct 2017 Results published in the Annals of Pharmacotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top